Strategically Aligning Information Technology and Biochemical Sciences
SEATTLE, May 22 /PRNewswire/ -- Immunex Corporation (Nasdaq: IMNX)
announced today that Carl March, Ph.D. has been promoted to senior vice
president, information technology and biochemical sciences. This is a
promotion from his current position of vice president of biochemical sciences.
In addition to his leadership responsibilities for biochemical sciences,
Dr. March, 48, will take on responsibility for applying information technology
to basic science and business process management.
"Carl has demonstrated vision and passion for the application of
information technology to basic science," said Doug Williams, executive vice
president and chief technology officer. "In addition to his deep knowledge of
Immunex science he has established his leadership in exploiting the burgeoning
scientific opportunities and moving drug discoveries from the bench to the
marketplace."
Dr. March received his Ph.D. in chemistry from Purdue University in 1980.
Following his postdoctoral fellowship at Baylor College of Medicine in 1983,
he joined Immunex as an associate staff scientist.
Immunex Corporation is a biopharmaceutical company dedicated to improving
lives through immune system science innovations.
NOTE: Except for the historical information contained herein, this news
release contains forward-looking statements that involve substantial risks and
uncertainties. Among the factors that could cause actual results or timelines
to differ materially are risks associated with research and clinical
development, regulatory approvals, our supply capabilities and reliance on
third-party manufacturers, product commercialization, competition, litigation
and other risk factors listed from time to time in reports filed by Immunex
with the SEC, including but not limited to risks described under the caption
"Important Factors That May Affect Our Business, Our Results of Operations and
Our Stock Price" within our most recently filed Form 10-Q. The
forward-looking statements contained in this news release represent our
judgment as of the date of this release. Immunex undertakes no obligation to
publicly update any forward-looking statements. An electronic version of this
news release -- as well as additional information about Immunex of interest to
investors, customers, future employees and patients -- is available on the
Immunex home page at http://www.immunex.com.
SOURCE Immunex Corporation
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/comp/434644.html or fax,
800-758-5804, ext. 434644
CONTACT:
Media, Kris Greco, 206-470-4871, or
Investors, Mark Leahy, 206-389-4363, both for Immunex Corporation
|
